23andMe Investor Presentation Deck

Large I/O market with $60B in 2021 sales Our I/O Programs Were Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature 2021 sales of leading checkpoint inhibitors KEYTRUDA $17.2B OPDIVO YERVOY $7.5B $2.0B 23andMe's proprietary I/O genetic signature developed with ML which also identifies marketed I/O drugs I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes ansfer or as payung Hypothyroidan Hyperthyidas- vei gh sout equ GHALL HEA M qanos o carcnon karoon tin tal- we cance Autoimmune Cancer We discovered additional targets that have a similar genetic I/O signature CD200R1 (23ME'610) CD96 (GSK'608) + others Copyright © 2022 23and Me, Inc. 23andMe 37

View entire presentation